Navigation Links
NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression
Date:9/6/2017

WILMINGTON, Del., Sept. 6, 2017 /PRNewswire/ -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug Administration for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin enrolling patients in a pivotal trial of this sequential therapy targeting patients who are admitted to Emergency Departments with ASIB in bipolar depression.1

Jonathan C. Javitt, MD, MPH, CEO, NeuroRx, Inc.
Jonathan C. Javitt, MD, MPH, CEO, NeuroRx, Inc.
NeuroRx phase 2 results of NRX-100 (ketamine) followed by NRX-101 (D-cycloserine + lurasidone) demonstrating 50% reduction in symptoms of depression, accompanied by 75% reduction in suicidal ideation. Adapted from Kantrowitz, et. al.,Journal of Clinical Psychiatry, 2015
NeuroRx phase 2 results of NRX-100 (ketamine) followed by NRX-101 (D-cycloserine + lurasidone) demonstrating 50% reduction in symptoms of depression, accompanied by 75% reduction in suicidal ideation. Adapted from Kantrowitz, et. al.,Journal of Clinical Psychiatry, 2015

Fast Track Designation is awarded by the FDA to investigational drugs that are deemed by FDA to treat a serious medical condition and for which there is preclinical and/or clinical data to demonstrate that the drug has the potential to address an unmet medical need. Suicidality in Bipolar Depression is a condition for which there is currently no approved drug therapy and for which the only FDA-approved treatment is Electroconvulsive Therapy (ECT).

Jonathan Javitt, M.D., M.P.H., the Company's Chief Executive Officer, will update investors on the Company's progress towards the planned October 2017 initiation of its upcoming clinical trial and recently issued claims at the upcoming Rodman and Renshaw Global Investment Conference, being held on September 11 and 12 at the New York Palace Hotel. In addition, the company is available to conduct one-on-one meetings with registered attendees of the conference. The presentation will be webcast.

Rodman and Renshaw Global Investment Conference Presentation Details

Date:

Tuesday, September 12

Time:

5:30 PM Eastern Time

About Bipolar Depression and Acute Suicidal Ideation & Behavior

Bipolar disorder, which affects 5.7 million Americans, is characterized by significant changes in mood, from mania or hypomania, to depression, often quite severe. The depressive phase, which is called "bipolar depression" can trigger thoughts of suicidal thoughts and behaviors. Standard of care consists of hospitalized observation and electroconvulsive therapy (ECT). Unfortunately, most commonly used antidepressants bear an FDA-mandated warning label identifying the potential to increase the risk of suicide.

Each day, approximately 100 Americans, and more than 2,100 people worldwide, end their lives by suicide, according to American Foundation for Suicide Prevention (AFSP) and the World Health Organization (WHO). Although only 10% of all people with depression have bipolar depression, NeuroRx estimates that bipolar depression accounts for nearly half of all suicides each year.

About NRX-101

NRX-101 is a patented, oral, fixed-dose combination of two FDA-approved drugs: d-cycloserine, a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NeuroRx's investigational treatment approach begins with a single dose of NRX-100 (ketamine), an FDA-approved anesthetic, for initial stabilization, followed by approximately six weeks of daily oral NRX-101. Results from two Phase II clinical studies, involving 26 and 8 patients respectively, have been published in peer-reviewed journals. Findings showed a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation in bipolar patients who were on background antidepressant therapy and then treated with d-cycloserine, one of the active ingredients in NRX-101.

About NeuroRx, Inc.

NeuroRx draws upon 30 years of basic science and clinical expertise in the role of the N-methyl-D-aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality. The company is privately funded and led by former senior executives of Johnson and Johnson, Pfizer, Lilly, and Bristol Meyer Squibb.

Learn more at NeuroRxpharma.com.

Contact:
Investor Relations:
Michael Rice                                                  
LifeSci Advisors, LLC                                  
+1-917-282-3242                                           
mrice@LifeSciAdvisors.com                         

PR:
Deanne Eagle
Planet Communications
+1-917-837-5866
175105@email4pr.com

1 Details of the clinical trial may be viewed on www.clinicaltrials.gov under the identifier NCT02974010.

View original content with multimedia:http://www.prnewswire.com/news-releases/neurorx-awarded-fda-fast-track-designation-for-first-drug-regimen-targeting-suicide-in-bipolar-depression-300514652.html


'/>"/>
SOURCE NeuroRx, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression & Suicidality
2. American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression
3. NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data
4. AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
5. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
6. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
7. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
8. Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
9. Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies
10. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
11. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
Breaking Medicine Technology:
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):